Coenzyme Q0 immobilized on Magnetic Nanoparticle: Synthesis and Antitumoral Effect on Saos, MCF7 and Hela Cell Lines

Document Type : Research article


1 Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.

2 Department of Basic Sciences, Mazandaran University of Science & Technology (MUST), Babol, Iran.

3 Cellular and Molecular Biology Research Center (CMBRC), Health Research Institute, Babol University of Medical Sciences, Babol, Iran.


 Many attempts in medical community focused on the preparation of anticancer agents. Various Coenzyme Q such as CoQ0 analogs have been reported as anti-inflammatory, anticancer, and antioxidant substances. In this study a novel derivatives of Coenzyme Q as an anticancer agent have been introduced. The prepared magnetic nanoparticle, containing CoQ0 were prepared using common chemical methods and also characterized by means of nuclear magnetic resonance (NMR), fourier transform infrared (FT-IR), thermal gravimetric analysis (TGA), and differential scanning calorimetric (DSC). To evaluate the antiproliferative effects of the nanoparticle, the prepared compound was treated with cell lines such as Hela, MCF-7 and Saos. Moreover, the outcomes were compared with normal fibroblast cell line. These assessments were performed by means of MTT assay. Investigation on the capability of this prepared nanoparticle showed some reliable results including cytotoxicities against MCF7, Saos and Hela cancer cell lines which were illustrated by displaying the morphology of the treated cells using AO/EB dual staining fluorescent technique. Employing simple method for preparation as well as the promising cytotoxic results makes it as a promising candidate for further bioexperiments.

Graphical Abstract

Coenzyme Q0 immobilized on Magnetic Nanoparticle: Synthesis and Antitumoral Effect on Saos, MCF7 and Hela Cell Lines


(1) Brannon Peppas L and Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. (2012) 64: 206-12.
(2) Feng SS and Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. (2003) 58: 4087-114.
(3)Sinha R, Kim GJ, Nie S and Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. (2006) 5: 1909-17. 
(4) Didi Nurhadi Illian, Poppy Anjelisa Zaitun Hasibuan, Sumardi Sumardi, Arif Nuryawan, Ridha Wati and Mohammad Basyuni. Iran. J.Pharm. Res. (2019) 18: 1477-87
(5) Maryam Baharloui, Sayed Ahmmad Mirshokraee, Azam Monfared and Mohammad Hassan Houshdar Tehrani. Iran. J. Pharm. Res. (2019), 18: 1299-308
(6) Peyman Kheirandish Zarandi, Abbas Zare Mirakabadi and Fattah Sotoodehnejad nematalahi.  Iran. J. Pharm. Res. (2019) 18: 232-40
(7) Meysam Soleimani, Hamid Mirmohammmad Sadeghi and Ali Jahanian Najafabadi. Iran. J. Pharm Res. (2019) 18: 735-744
(8) Farokhzad OC and Langer R. Impact of nanotechnology on drug delivery. ACS Nano. (2009) 3: 16-20.
(9) Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. (2006) 8: 343-75.
(10) Nori A, Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv. Rev. (2005) 57: 609-36.
(11) Cho K, Wang X, Nie S,Chen Z and Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. (2008) 14: 1310-6. 
(12) Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control Release. (2011) 153: 198-205.
(13) Maedeh Akbarian, Soleiman Mahjoub, Seyed Mohammad Elahi, Ebrahim Zabihi, Hamed Tashakkorian. Green synthesis, formulation and biological evaluation of a novel ZnO nanocarrier loaded with paclitaxel as drug delivery system on MCF-7 cell line. Colloids Surf B Biointerfaces. (2020) 186: 110686
(14) Cheng R, Feng F, Meng F, Deng C, Feijen J and Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J. Control Release. (2011) 152: 2-12.
(15) Panyam J and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. (2003) 55: 329-47.
(16) Karim E, Rosli R and H Chowdhury E. Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer. Curr. Canc Ther. Rev. (2016) 12: 204-20. 
(17) Silva AKA, Silva EL, Carvalho JF, Pontes TRF, Neto RPdA, Carriço AdS, et al., editors. Drug targeting and other recent applications of magnetic carriers in therapeutics. Key Eng Materials. (2010) 441: 357-378
(18) Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R and Hubalek J. Magnetic nanoparticles and targeted drug delivering. Pharmacol. Res. (2010) 62: 144-9.
(19) Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano. Today (2007) 2: 22-32.
(20) Revia RA and Zhang M. Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances. Mater Today. (2016) 19: 157-68.
(21) Arias J, Gallardo V, Gomez-Lopera S, Plaza R and Delgado A. Synthesis and characterization of poly (ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J. Control Release. (2001) 77: 309-21.
(22) Boyer C, Whittaker MR, Bulmus V, Liu J and Davis TP. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Materials. (2010) 2: 23-30.
(23) Baalousha M, Manciulea A, Cumberland S, Kendall K and Lead JR. Aggregation and surface properties of iron oxide nanoparticles: influence of pH and natural organic matter. Environ Toxicol Chem. (2008) 27: 1875-82.
(24) Turunen M, Olsson J and Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta. (2004) 1660: 171-99.
(25) Devun F, Walter L, Belliere J, Cottet-Rousselle C, Leverve X and Fontaine E. Ubiquinone analogs: a mitochondrial permeability transition pore-dependent pathway to selective cell death. PLoS One (2010) 5: e11792.
(26) Somers Edgar TJ and Rosengren RJ. Coenzyme Q0 induces apoptosis and modulates the cell cycle in estrogen receptor negative breast cancer cells. Anticancer Drugs (2009) 20: 33-40.
(27) Yang HL, Lin MW, Korivi M, Wu JJ, Liao CH, Chang CT, et al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in-vitro and in-vivo studies. Biochim Biophys Acta (2016) 1859: 246-61.
(28) Yang HL, Korivi M, Lin MW, Chen S-C, Chou CW and Hseu YC. Anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling in TNF-α-activated human endothelial cells. Biochemical pharmacology. (2015) 98: 144-56.
(29) Wang HM, Yang HL, Thiyagarajan V, Huang TH, Huang P-J, Chen SC, et al. Coenzyme Q0 enhances ultraviolet B–induced apoptosis in human estrogen receptor–positive breast (MCF-7) cancer cells. Integr Cancer Ther. (2017) 16: 385-96.
(30) Lakouraj MM, Hasantabar V, Tashakkorian H, Golpour M. Novel anticancer and antibacterial organometallic polymer based on ferrocene as a building block and xanthone bioactive scaffolds: Synthesis, characterization, and biological study. Polymer Adv Tech. (2018) 29: 2784-96.
(31) Khan F, Akhtar S, Almofty S, Almohazey D, Alomari M. FMSP-nanoparticles induced cell death on human breast adenocarcinoma cell line (MCF-7 Cells): Morphometric Analysis. Biomolecules. (2018) 8: 32.
(32) Kolosnjaj-Tabi J and Wilhelm C. Magnetic nanoparticles in cancer therapy: how can thermal approaches help? : Nanomedicine. (2017) 12: 573-575.
(33) Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer (2002) 2: 750-63.
(34) Lenaz G, Fato R, Formiggini G and Genova ML. The role of Coenzyme Q in mitochondrial electron transport. Mitochondrion (2007) 7: S8-S33.
(35) Chung CH, Yeh SC, Chen CJ and Lee KT. Coenzyme Q0 from Antrodia cinnamomea in Submerged Cultures Induces Reactive Oxygen Species-Mediated Apoptosis in A549 Human Lung Cancer Cells. Evid Based Complement Alternat Med. (2014) 2014: 246748.